Improved survival in multiple myeloma with renal failure

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Multiple myeloma with advanced tumor burden and renal impairment presents a significant clinical challenge.
• Standard treatment outcomes for these patients are often poor, necessitating exploration of intensive therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of intensive chemotherapy combined with plasmapheresis in multiple myeloma patients with significant renal dysfunction.
• To compare survival rates between different treatment protocols in this high-risk patient population.

Main Methods:

• A cohort of 44 multiple myeloma patients with stage III B renal failure (S-creatinine > 2 mg/dl) was studied.
• Treatment groups included no active treatment, melphalan-prednisolone, and a combination chemotherapy M-2 protocol with plasmapheresis.
• Survival data was analyzed and compared between groups.

Main Results:

• Patients receiving no active treatment had a median survival of less than 1 month.
• The M-2 protocol with plasmapheresis resulted in a significantly longer median survival of 17 months (p < 0.01) compared to melphalan-prednisolone (median 2 months).
• Improvements in supportive care, including dialysis and antibiotics, may have also contributed to better outcomes.

Conclusions:

• Intensive chemotherapy, plasmapheresis, and aggressive uremia management including dialysis are recommended for advanced multiple myeloma with renal failure.
• This multimodal approach offers a survival benefit in a patient group with historically poor prognosis.
• Further research into optimizing supportive care alongside intensive treatments is warranted.